Targeted immunotherapies for Graves’ thyroidal & orbital diseases
BackgroundGraves’ hyperthyroidism and its associated Graves’ orbitopathy are common autoimmune disorders associated with significant adverse health impact. Current standard treatments have limitations regarding efficacy and safety, and most do not specifically target the pathogenic mechanisms. We ai...
Saved in:
| Main Authors: | Alan Chun Hong Lee, George J. Kahaly |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1571427/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A randomized controlled trial on the effect of hydroxychloroquine in mild Graves’ orbitopathy (GO-HCQ): study protocol
by: Chia-Hung Lin, et al.
Published: (2025-08-01) -
Graves’ Disease: Is It Time for Targeted Therapy? A Narrative Review
by: Nicola Viola, et al.
Published: (2025-03-01) -
Radiological Features of Thyroid Eye Disease (TED)
by: Ayushi Agarwal, et al.
Published: (2020-10-01) -
Transnasal endoscopic orbital decompression in Graves’ disease: experience of 20 years in Hospital of Egas Moniz
by: Luís André Baptista, et al.
Published: (2024-12-01) -
The role of IL-6 in thyroid eye disease: an update on emerging treatments
by: Jennifer Murdock, et al.
Published: (2025-04-01)